BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 9860826)

  • 1. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
    Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
    Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure/function analysis of a dUTPase: catalytic mechanism of a potential chemotherapeutic target.
    Harris JM; McIntosh EM; Muscat GE
    J Mol Biol; 1999 Apr; 288(2):275-87. PubMed ID: 10329142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic activity of purified avian sarcoma and leukemia virus NC-PR protein expressed in Escherichia coli.
    Séllos-Moura M; Vogt VM
    Virology; 1996 Jul; 221(2):335-45. PubMed ID: 8661444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays.
    Kuhelj R; Rizzo CJ; Chang CH; Jadhav PK; Towler EM; Korant BD
    J Biol Chem; 2001 May; 276(20):16674-82. PubMed ID: 11278433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoprocessing of HIV-1 protease is tightly coupled to protein folding.
    Louis JM; Clore GM; Gronenborn AM
    Nat Struct Biol; 1999 Sep; 6(9):868-75. PubMed ID: 10467100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of human immunodeficiency virus type 1 containing HERV-K protease.
    Padow M; Lai L; Fisher RJ; Zhou YC; Wu X; Kappes JC; Towler EM
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1973-80. PubMed ID: 11153080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease.
    Wondrak EM; Louis JM
    Biochemistry; 1996 Oct; 35(39):12957-62. PubMed ID: 8841142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
    Rose RB; Craik CS; Stroud RM
    Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
    Lindhofer H; von der Helm K; Nitschko H
    Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mutations on the dimer stability and the pH optimum of the human foamy virus protease.
    Sperka T; Boross P; Eizert H; Tözsér J; Bagossi P
    Protein Eng Des Sel; 2006 Aug; 19(8):369-75. PubMed ID: 16799151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of intracellular human immunodeficiency virus type-1 protease activity.
    Gatlin J; Arrigo SJ; Schmidt MG
    Virology; 1998 Apr; 244(1):87-96. PubMed ID: 9581782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and purification of active form of HIV-1 protease from E.coli.
    Wan M; Loh BN
    Biochem Mol Biol Int; 1995 Apr; 35(4):899-912. PubMed ID: 7627139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant.
    Moody MD; Pettit SC; Shao W; Everitt L; Loeb DD; Hutchison CA; Swanstrom R
    Virology; 1995 Mar; 207(2):475-85. PubMed ID: 7886951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
    Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
    Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bovine leukemia virus: purification and characterization of the aspartic protease.
    Menard A; Mamoun RZ; Geoffre S; Castroviejo M; Raymond S; Precigoux G; Hospital M; Guillemain B
    Virology; 1993 Apr; 193(2):680-9. PubMed ID: 8384751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis.
    Strisovsky K; Tessmer U; Langner J; Konvalinka J; Kräusslich HG
    Protein Sci; 2000 Sep; 9(9):1631-41. PubMed ID: 11045610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structural model for the retroviral proteases.
    Pearl LH; Taylor WR
    Nature; 1987 Sep 24-30; 329(6137):351-4. PubMed ID: 3306411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
    Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
    Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.